Rhodiola Rosea: Clinical Dose Ranges and What the Research Describes

What rhodiola rosea is

Rhodiola rosea is a flowering plant native to arctic and mountainous regions of Europe and Asia, sometimes called golden root or arctic root. It is classified as an adaptogen and has a long history of traditional use in Russia and Scandinavia. The primary active compounds identified in research are rosavins (tricinol, rosavin, and rosarin) and salidroside. Standardised extracts typically specify at least 3% rosavins and 1% salidroside.

For a broader look at what the research says about rhodiola and fatigue, see: Rhodiola rosea: what the research shows.

The clinical dose range

SHR-5 (a specific Rhodiola rosea extract) is the formulation used in the most-cited fatigue trials and is considered the reference extract in the literature.

What trials have measured

The most consistently positive trial findings for rhodiola rosea relate to self-reported mental fatigue, particularly in stressful conditions. A trial by Shevtsov et al. (2003) in physicians working night shifts found significant improvements in fatigue measures after a single 170 mg dose of SHR-5. A 2009 trial in students during examination periods found reduced fatigue and improved cognitive performance at 400 mg/day.

Physical performance — specifically exercise endurance and time to exhaustion — has been measured in several trials with inconsistent results. A 2015 meta-analysis found a statistically significant but small improvement in time-to-exhaustion tests. More recent reviews, including a 2025 systematic review and meta-analysis, found modest improvements in endurance performance metrics but cautioned that trial quality is generally low.

Mood and anxiety outcomes have been measured in open-label and randomised trials with inconsistent results; several studies have been conducted by researchers with industry ties, which warrants caution in interpreting the findings.

Underdosing in commercial products

Rhodiola rosea faces a compounded problem in commercial products: underdosing and species substitution.

• Low extract doses: Many products include 100–150 mg of extract per serving — below the 200 mg lower bound of the trial range.
• Species substitution: Related species (Rhodiola crenulata, Rhodiola imbricata) are visually and chemically similar but lack the characteristic rosavin profile of Rhodiola rosea. Laboratory analyses have found species substitution in a notable proportion of commercial products.
• Missing standardisation: Products that do not specify rosavins and salidroside content cannot be assessed against trial protocols.

Documented safety considerations

Rhodiola rosea is generally considered safe in short-term use at the studied doses. Reported adverse effects are mild and include dizziness, dry mouth, and agitation, particularly at higher doses. There is limited long-term safety data. Potential interactions with monoamine oxidase inhibitors (MAOIs), anticoagulants, and hypoglycaemic agents have been proposed on mechanistic grounds; clinical data on interactions is limited.

As with all herbal supplements, individuals taking prescription medication or with existing health conditions should consult a clinician before use.

How Proco Scanner evaluates it

When the Scanner reads rhodiola rosea, it checks whether the extract is standardised to rosavins and salidroside, whether the species is specified as Rhodiola rosea, and whether the dose falls within the 200–600 mg/day range used in trials. Products without standardisation information or species verification are flagged accordingly.

Proco Scanner reads any supplement label and surfaces what the published research describes for each ingredient — dose, evidence quality, and known considerations. Coming to iOS. Join the waitlist for early access.